Daily non-political popular news in brief.

Anti-malarial drug may reduce risk of diabetes for patients with rheumatoid arthritis

Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA.

Read more »

Keywords: anti-malarial, drug, risk, diabetes, patients, rheumatoid, arthritis, anti, malarial, diabete, patient, arthriti

« Previous | Next »

Similar news on "Anti-malarial drug may reduce risk of diabetes for patients with rheumatoid arthritis":

1. Common rheumatoid arthritis treatment shows potential for diabetes prevention
   07-10-2007 · EurekAlert!
   Fewer rheumatoid arthritis patients treated with the drug hydroxychloroquine went on to develop diabetes compared to those who never took the drug, according to a 20-plus-year University of Pittsburgh School of Medicine-led study reported today in the Journal of the American Medical Association. In addition, those using HCQ were less likely to take medications to manage diabetes after diagnosis. The study found risk declined a dramatic 77 percent after four years of HCQ treatment.
   Similar news · Read more »
   
2. Annals of Internal Medicine tip sheet for March 20, 2007
   03-19-2007 · EurekAlert!
   The following articles are featured in the upcoming Annals of Internal Medicine: "Flexible Use of Drugs with Close Patient Follow-up Can Successfully Control Rheumatoid Arthritis;" "Osteoporosis Drug Strengthens Bones in Men with Prostate Cancer," and "Experts Show Physicians How to Initiate and Carry Through Timely and Effective Discussions about Hospice with Dying Patients."
   Similar news · Read more »
   
3. JCI table of contents: December 1, 2006
   12-01-2006 · EurekAlert!
   This release contains summaries, links to PDFs, and contact information for newsworthy papers to be published December 1, 2006, in the JCI, including: Silencing the cause of mad cow disease; Immune responses spread from one protein to another in type 1 diabetes; Fat tissue gains weight from the bone marrow; Immune cells get together in the lung of patients with rheumatoid arthritis; PDE3B regulates energy levels in mice; and others.
   Similar news · Read more »
   
4. Combining medications often best strategy to battle rheumatoid arthritis
   11-19-2007 · EurekAlert!
   For patients with rheumatoid arthritis, combining one well-known, lower-cost synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness, according to a new report by researchers at the RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center.
   Similar news · Read more »
   
5. One-fifth of patients in drug-free remission following early treatment with Infliximab and Methotrex
   06-14-2007 · EurekAlert!
   Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
   Similar news · Read more »
   
6. Rheumatoid arthritis sends many into early retirement
   02-04-2008 · EurekAlert!
   A joint study on "The Burden of Rheumatoid Arthritis and Patient Access to Treatments" by authors from the Stockholm School of Economics, the University of Lund and the Medical University of Vienna has shown that the highest cost in rheumatoid arthritis results from patients having to leave the workforce early due to the disease. The study has just been published online in a supplement to Springer's The European Journal of Health Economics.
   Similar news · Read more »
   
7. Drug's potential adverse side effect explained
   09-06-2007 · EurekAlert!
   Drugs that are agonists of the receptor PPAR-gamma are used to treat individuals with diabetes. However, it has been suggested that their use is associated with a slightly increased risk of heart failure. A potential explanation for this adverse effect that is observed in a minority of patients is outlined in a new study in the Journal of Clinical Investigation.
   Similar news · Read more »
   
8. Prescribing information for kidney disease far too vague
   12-06-2006 · EurekAlert!
   Prescribing information for healthcare professionals treating patients with kidney disease is too vague, concludes the latest issue of Drug and Therapeutics Bulletin (DTB). Many of the 4-5 percent of the UK population with serious chronic kidney disease are elderly people, who are often taking several different drugs. Other risk factors for the disease include diabetes and high blood pressure.
   Similar news · Read more »
   
9. 1/5 of patients in drug-free remission following early treatment with Infliximab and Methotrex
   06-14-2007 · EurekAlert!
   Early treatment with a combination of methotrexate and infliximab may be effective as remission induction therapy and alter the course of early rheumatoid arthritis, according to data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.
   Similar news · Read more »
   
10. New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
    11-08-2007 · EurekAlert!
    The innovative new rheumatoid arthritis drug Actemra has been shown to significantly improve the signs and symptoms of rheumatoid arthritis in patients who failed to achieve an adequate response to traditional disease modifying agents. Exciting new data from the TOWARD1 study, being presented as a late breaker, at the American College of Rheumatology Annual Scientific Meeting in Boston, Nov. 6-11, reinforce the benefit of tackling RA through the inhibition of the IL-6 pathway.
    Similar news · Read more »